Home   >  

Classified by application

All Products

Signaling Pathways

Research Areas

Nature products






Raw Materials

Angiogenesis/Protein Tyrosine Kinase

Chemical Structure Cat. No. Product Name CAS No.
Sunitinib Chemical Structure
BCP02336 Sunitinib 557795-19-4
Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
QL-1200186 Chemical Structure
BCP49631 QL-1200186 2848664-42-4
QL-1200186 is an orally active and selective TYK2 inhibitor.
Befotertinib Chemical Structure
BCP49575 Befotertinib 1835667-63-4
Befotertinib is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).
Efruxifermin Chemical Structure
BCP49432 Efruxifermin 2375240-92-7
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21).
OPT-302 Chemical Structure
BCP49401 OPT-302 OPT-302
OPT-302 is a novel inhibitor of vascular endothelial growth factor (VEGF)-C and VEGF-D.
Batiraxcept Chemical Structure
BCP49357 Batiraxcept 2268717-61-7
Batiraxcept is an ultra-high affinity decoy protein that captures GAS6, preventing it from activating AXL signaling.
APS-03118 Chemical Structure
BCP49314 APS-03118 APS-03118
APS03118 is a novel next-generation RET inhibitor which is potent against a range of RET fusions and mutations including both SFMs and gatekeeper mutations.
BCX-9250 Chemical Structure
BCP49293 BCX-9250 BCX-9250
BCX 9250, is an orally administered, small molecule, inhibitor of activin receptor-like kinase-2 (ALK2).
Certepetide Chemical Structure
BCP49241 Certepetide 2580154-02-3
Certepetide is a bifunctional cyclic peptide (a.k.a. iRGD).
Tuspetinib hydrate Chemical Structure
BCP49212 Tuspetinib hydrate 2758339-04-5
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC50s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells.
123下一页末页共 894 条记录 1 / 90 页